Clinical Trial Update: Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II clinical trial evaluating brexucabtagene autoleucel as consolidation therapy in relapsed/refractory and newly diagnosed B-cell acute lymphoblastic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Tecartus (brexucabtagene autoleucel)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia | Phase 1, Phase 2 | Status: RECRUITING